Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Ranolazine in Chronic Stable Angina with Coronary Artery Disease and Type 2 Diabetes Mellitus
2011-002273-29Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in stable angina, coronary arteriosclerosis and type 2 diabetes mellitus (T2DM) comparing Ranolazine with Placebo (2 arms). Primary endpoint: Average weekly angina frequency over the last 6 weeks of treatment. Started Aug 2011; status: completed.
02
Drugs
ranolazine
03
Conditions
stable anginacoronary arteriosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002273-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002273-29.